Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01504477 · ClinicalTrials.gov registry record · Phase 1
Panitumumab and Bortezomib for Patients With Advanced Colorectal Cancer
A Phase 1 study, sponsored by Georgetown University.
- Terminated
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT01504477: Clinical Trial Phase 1 study, sponsored by Georgetown University.
NCT01504477 is a Phase 1 study that was terminated before completion, run by Georgetown University. The registered enrollment target is 6 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (90% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01504477, a Phase 1 study, was terminated before completion, sponsored by Georgetown University.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
Panitumumab plus bortezomib for colon cancer
Primary Outcome
The maximum tolerated dose of bortezomib (to be used in combination with panitumumab)
Interventions
- DRUG Panitumumab and bortezomib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2011-12 |
| Est. Completion | 2014-02 |
| Phase | Phase 1 |
Why NCT01504477 stopped before completion
NCT01504477 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (90% lower).
The record links to 0 conditions, and to 1 intervention - of which Panitumumab and bortezomib is the first listed.
NCT01504477 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01504477 about?
NCT01504477 is a clinical study titled "Panitumumab and Bortezomib for Patients With Advanced Colorectal Cancer". Panitumumab plus bortezomib for colon cancer
What is the current status of trial NCT01504477?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2011-12. Estimated completion is 2014-02.
What interventions are being tested in trial NCT01504477?
The interventions under investigation include: Panitumumab and bortezomib (DRUG).
Who is sponsoring clinical trial NCT01504477?
This trial is sponsored by Georgetown University, which has 227 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01504477's enrollment target sits among peer trials
6 1974th of 2000 higher than 12 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia